🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

MaxCyte, Inc. MXCT R2K

Healthcare · Medical Devices · United States
https://www.maxcyte.com

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

READ MORE ›
$1.21
-49.16% 1Y

Market & Price

Market Cap
$129.62M
Current Price
$1.21
High / Low (52W)
$2.39 / $0.68
Beta
1.57

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$1.57
Price to Book
0.77
P/S
4.01
EV/EBITDA
-1.18
Dividend Yield
-

Profitability & Returns

ROCE
-24.06%
ROE
-21.30%
ROA
-11.32%
Profit Margin
-
Op Margin
-64.09%
EPS (Latest Qtr)
$-0.04
EPS (TTM)
$-0.36

Balance Sheet & Liquidity

Debt/Equity
0.10
Quick Ratio
10.88
Current Ratio
12.04
Debt
$17.49M
Total Assets
$202.51M
Current Assets
$118.37M
Working Capital
$104.10M

Ownership

Promoter Holding
1.37%
Chg in Prom Hold
-
FII / Inst Holding
67.96%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$40.25M
Total Revenue (TTM)
$32.29M
EBITDA
$-34.16M
Free Cash Flow
$-14.13M
Operating Cash Flow
$-28.17M
Shares Outstanding
107.12M
Gross Margin
80.51%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-9.30%
Profit 5Y
-29.78%
Revenue (YoY)
-7.10%
Earnings (YoY)
-

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -9.3% CAGR over 5 years.
  • Earnings shrank at -29.8% CAGR over 5 years.
  • Trading 49.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MXCT MaxCyte, Inc. R2K 1.21 - $129.62M - -24.06% -21.30% -9.30% -29.78%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
⚙Ad space

Quarterly Results

Figures in USD.

Metric Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -2.33M4.67M4.24M4.22M5.61M6.86M6.98M7.15M4.96M5.62M4.16M5.58M4.96M-10.39M8.51M6.83M7.30M9.65M
Cost of Revenue ---------------1.50M1.52M1.60M1.61M1.57M
Gross Profit -4.68M6.03M5.80M6.32M9.20M10.52M8.49M9.27M7.58M7.67M7.21M9.94M8.94M-8.89M6.99M5.23M5.69M8.08M
Operating Expenses ---------------21.19M21.21M16.32M13.36M14.27M
Operating Income --2.84M-2.84M-6.37M-4.42M-2.44M-4.16M-8.74M-7.71M-13.18M-13.07M-13.95M-12.28M-11.97M--12.29M-14.23M-11.09M-7.67M-6.18M
EBITDA ----------------11.02M-13.15M-10.05M-6.38M-4.92M
Interest Expense --------------------
Pretax Income ----------------10.26M-12.36M-12.42M-9.60M-4.75M
Tax Provision ---------------00000
Net Income -3.06M-3.00M-3.10M-7.11M-4.42M-2.68M-4.07M-8.26M-6.43M-10.88M-10.51M-11.25M-9.53M-9.38M--10.26M-12.36M-12.42M-9.60M-4.75M
Diluted EPS --0.05-0.04-0.09-0.05-0.03-0.04-0.08-0.06-0.11-0.10-0.11--0.09--0.10-0.12-0.12-0.09-0.04
R&D Expense -4.09M4.52M6.08M3.20M2.75M3.77M4.70M5.33M6.05M5.66M6.26M6.68M5.62M5.32M5.90M6.27M5.32M-3.86M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 13.26M15.45M-44.26M41.29M38.63M33.03M
Cost of Revenue ---5.10M4.74M7.10M6.22M
Gross Profit 19.12M23.40M-39.16M36.55M31.53M26.80M
Operating Expenses ---66.52M84.84M82.72M72.09M
Operating Income -12.42M-11.06M--27.36M-48.30M-51.20M-45.28M
EBITDA ----24.66M-43.73M-46.41M-40.14M
Interest Expense --1.04M126.90K---
Pretax Income ----23.57M-37.92M-41.05M-44.63M
Tax Provision ---0000
Net Income -12.89M-11.82M--23.57M-37.92M-41.05M-44.63M
Diluted EPS -0.23-0.17--0.23-0.37-0.39-0.42
R&D Expense 17.59M17.73M15.41M19.51M23.82M22.23M20.82M

Compounded Sales Growth

5 Years:-9.30%
1 Year:-7.10%

Compounded Profit Growth

5 Years:-29.78%
1 Year:-

Stock Price Performance

1 Year:-49.16%
6 Months:-28.82%
3 Months:+49.20%
1 Month:+47.92%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --51.78M-286.65M268.27M239.47M202.51M
Current Assets ----252.27M190.19M171.68M118.37M
Cash & Equivalents --18.76M-11.06M46.51M27.88M20.07M
Inventory ----8.58M12.23M8.91M7.55M
Receivables ----13.09M5.78M4.68M3.50M
Total Liabilities --18.55M-32.69M36.11M33.22M31.02M
Current Liabilities --11.61M-15.43M17.86M15.78M14.27M
Long Term Debt --------
Total Debt ----16.09M18.74M18.03M17.94M
Total Equity 12.28M13.60M33.23M-253.97M232.17M206.25M171.49M
Shares Outstanding ----102.40M103.96M105.71M106.79M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -8.80M-8.78M--14.78M-21.69M-27.61M-34.41M
Investing Cash Flow 454.50K-16.58M--24.82M54.98M6.93M25.93M
Financing Cash Flow 12.31M28.90M-2.89M2.14M2.06M656.00K
Capital Expenditure -1.27M-2.07M--18.48M-3.70M-1.65M-1.77M
Free Cash Flow -10.07M-10.85M--33.26M-25.39M-29.26M-36.18M
Net Change in Cash ----36.72M35.44M-18.62M-7.82M

Ratios (Annual)

Figures in %.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 144.2%151.5%-88.5%88.5%81.6%81.2%
Operating Margin % -93.7%-71.6%--61.8%-117.0%-132.5%-137.1%
Net Margin % -97.3%-76.5%--53.3%-91.8%-106.3%-135.1%
ROE % -94.8%-35.6%--9.3%-16.3%-19.9%-26.0%
ROCE % --27.5%--10.1%-19.3%-22.9%-24.1%

Shareholding Pattern

Insiders
1.37%
Institutions
67.96%
Public Float
68.90%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.21% 8.80M $10.65M
2 Capricorn Fund Managers Ltd 7.65% 8.20M $9.92M
3 Vitruvian Partners, LLP 4.71% 5.04M $6.10M
4 Vanguard Capital Management LLC 3.72% 3.98M $4.82M
5 Morgan Stanley 3.44% 3.69M $4.46M
6 Mudita Advisors LLP 3.15% 3.37M $4.08M
7 BNP Paribas Asset Management Holding S.A. 2.59% 2.77M $3.36M
8 Geode Capital Management, LLC 2.21% 2.36M $2.86M
9 State Street Corporation 2.05% 2.19M $2.65M
10 Brooklands Fund Management Ltd 2.04% 2.19M $2.65M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MXCT

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space